Affinivax
25 articles about Affinivax
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
6/21/2022
Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease.
-
The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.
-
GSK announced that it is acquiring Affinivax for up to $3.3 billion to gain its novel class of developmental vaccines and its MAPS technology.
-
Affinivax to Highlight Preclinical Data from COVID-19 MAPS™ Vaccine Development Program at IMMUNOLOGY2022™
5/2/2022
Affinivax, Inc. today announced the company will present a poster highlighting COVID-19 MAPS™ vaccine non-human primate data at IMMUNOLOGY2022™, the annual meeting of the American Association of Immunologists (AAI) in Portland, Oregon (May 6-10, 2022.
-
Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS™ Platform
2/28/2022
Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.
-
Affinivax to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:30 a.m. ET.
-
Affinivax Appoints Rick Malley, MD, as Chief Scientific Officer
12/22/2021
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) technology platform, today announced the appointment of Dr. Rick Malley as Chief Scientific Officer.
-
Affinivax Appoints Vanya Sagar as Chief People Officer
12/16/2021
Affinivax, Inc. today announced the appointment of Vanya Sagar, M.P.A., as its Chief People Officer.
-
Affinivax Appoints Kara Bickham, MD, as Chief Medical Officer
8/9/2021
Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ platform, announced that Kara Bickham, MD, has joined the company as Chief Medical Officer.
-
The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.
-
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
7/12/2021
Affinivax, Inc. and Astellas Pharma Inc. announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.
-
Affinivax Appoints Elizabeth Radcliffe as Chief Financial Officer
5/5/2021
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.
-
Money on the Move – March 3-9
3/10/2021
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week. -
Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials
3/9/2021
Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens
-
Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases
1/8/2021
Lead pneumococcal vaccine in clinical development offers potential for broader protection than any vaccine on the market or in clinical trials today
-
Affinivax to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/2021
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will deliver a company presentation at the 39 th Annual J.P. Morgan Healthcare Confer
-
Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies
4/23/2020
Lead pneumococcal vaccine currently in clinical trials designed to provide broadest protection
-
Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance its vaccine and immunotherapy candidates.
-
BioSpace Movers and Shakers: April 19
4/19/2019
Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.